{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-037486","form_type":"8-K","ticker":"STOK","cik":"0001623526","company_name":"Stoke Therapeutics, Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.474555+00:00","generated_at":"2026-06-21T20:25:00.641629+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Stoke reports positive interim Phase 1/2a data for STK-001 in Dravet syndrome; 55% median seizure reduction at 45mg","bullets":["STK-001 up to 45mg well-tolerated; 55% median reduction in convulsive seizures with three doses of 45mg (n=6).","74% of patients (20/27) experienced reduction in seizure frequency after three doses of STK-001.","Cash of $252.2M as of Sep 30, 2022 expected to fund operations into 2025; Q3 net loss $26.1M ($0.66/share).","FDA granted Rare Pediatric Disease Designation for STK-001 in Dravet syndrome in October 2022.","Planned data updates on multiple doses of 45mg and 70mg in 2023; AES presentation Dec 2-6."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-037486","json":"https://secwatch.observer/filing/0001564590-22-037486.json","markdown":"https://secwatch.observer/filing/0001564590-22-037486.md","text":"https://secwatch.observer/filing/0001564590-22-037486.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1623526/000156459022037486/0001564590-22-037486-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1623526/000156459022037486/stok-8k_20221114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T20:25:00.641629+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f9b2eea8b73affd54c057d2c3e31991ac5cb2296","claim":"Stoke Therapeutics, Inc. reported financial results for the third quarter of 2022.","evidence_excerpt":"Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the third quarter of 2022 and provided business updates, including positive data from a planned interim analysis of the ongoing Phase 1/2a MONARCH and ADMIRAL clinical studies of STK-001 in children and adolescents with Dravet syndrome.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1623526/000156459022037486/0001564590-22-037486-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter of 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}